Loading...

KYTX KYVERNA THERAPEUTICS INC Expansion Plans 8-K Filing

KYVR

KYTX

KYVERNA THERAPEUTICS INC

(KYTX)

2025 8-K

CFO Appointment

Business Update Issued

Management Change

Positive Trial Results

Positive Trial Results

Positive Clinical Data

Quarterly Earnings Update

Board Appointments

Management Change

Management Change

Stock Offering Details

Positive Data Release

Positive Trial Results

Business Update

Loan Agreement Funded

Positive Trial Results

Positive Data Release

Financial Statements

Stock Sale Agreement

Financial Results

Management Appointment

Strategic Priorities

Management Change

Financial Update

Director Appointment

Management Changes

External Links:

Kyverna Therapeutics, Inc. reported positive topline data on December 15, 2025, from its Phase 2 trial of mivocabtagene autoleucel for stiff person syndrome. The company will discuss these findings on a conference call the same day.

AI Assistant

KYVERNA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.